L608 Liposomal inhalation suspension not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.”In the company’s words, NCT06429930 on ClinicalTrials.gov
- Main trialPhase 1
- “This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.”In the company’s words, NCT06429930 on ClinicalTrials.gov
Coming up1
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Dec 2026 | Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026